Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting

Journal of Clinical Virology

Volumn 53, Issue 2, 2012, Pages 121-124

  Venturoli, Simona ^a   Leo, Elisa ^a   Nocera, Martina ^a   Barbieri, Daniela ^a   Cricca, Monica ^a   Costa, Silvano ^a   Santini, Donatella ^a   Zerbini, Marialuisa ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

HPV testing; HPV16 18 typing; Real time PCR; Referral population

Indexed keywords

VIRUS DNA;

ABBOTT REALTIME HIGH RISK HPV ASSAY; ADULT; AGED; ARTICLE; ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HYBRID CAPTURE 2 HIGH RISK HPV DNA ASSAY; INNO-LIPA HPV GENOTYPING EXTRA ASSAY; INTERMETHOD COMPARISON; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; VIRUS TYPING;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRUS INFECTIONS; REAGENT KITS, DIAGNOSTIC; REAL-TIME POLYMERASE CHAIN REACTION; REFERRAL AND CONSULTATION; REPRODUCIBILITY OF RESULTS; RISK; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84855558828     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.10.016     Document Type: Article

References (24)

1. Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen B.L., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002, 325(7364):572.
2. Schlecht N.F., Kulaga S., Robitaille J., Ferreira S., Santos M., Miyamura R.A., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001, 286:3106-3114.
3. Miller A.B., Nazeer S., Fonn S., Brandup-Lukanow A., Rehman R., Cronje H., et al. Report on consensus conference on cervical cancer screening and management. Int J Cancer 2000, 86:440-447.
4. practice bulletin A.C.O.G. Cervical cytology screening. Number 45, August 2003. Int J Gynaecol Obstet 2003, 83:237-247.
5. Wright T.C., Cox J.T., Massad L.S., Twiggs L.B., Wilkinson E.J. Consensus guidelines for the management of women with cervical cytological abnormalities. J Low Genit Tract Dis 2002, 6:127-143. 2001.
6. Wright T.C., Schiffman M., Solomon D., Cox J.T., Garcia F., Goldie S., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004, 103:304-309.
7. Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002, 52:342-362.
8. Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008, 17:3033-3042.
9. Meijer C.J.L.M., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. J Int Cancer 2009, 124:516-520.
10. Kjær S.K., Frederiksen K., Munk C., Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102:1478-1488.
11. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., ShermanM, Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97:1072-1079.
12. Huang S., Tang N., Mak W.B., Erickson B., Salituro J., Li Y., et al. Principles and analytical performance of Abbott RealTime High Risk HPV test. J Clin Virol 2009, 45(Suppl. 1):S13-S17.
13. Altman D.G., Mschin D., Bryant T.N., Gardner M.J. Statistics with confidence 2000, JW Arrowsmith Ltd., Bristol. 2nd ed.
14. Fleiss J.L. Statistical methods for rates and proportion 1981, John Wiley & Sons Inc., New York. 2nd ed.
15. Halfon P., Benmoura D., Agostinib A., Khiric H., Penaranda G., Martineau A., et al. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. J Clin Virol 2010, 48:246-250.
16. Poljak M., Kovanda A., Kocjan B.J., Seme K., Jančar N., Vrtačnik-Bokal E. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatoven APA 2009, 18:94-103.
17. Constandinou-Williams C., Collins S.I., Roberts S., Young L.S., Woodman C.B., Murray P.G. Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study. Cancer Epidemiol Biomarkers Prev 2010, 19:832-837.
18. Castle P.E., Solomon D., Wheeler C.M., Gravitt P.E., Wacholder S., Schiffman M. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008, 46:2595-2604.
19. van Doorn L.J., Quint W., Kleter B., Molijn A., Colau B., Martin M.T., et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY Line Blot Assay and the SPF10 Line Probe Assay. J Clin Microbiol 2002, 40:979-983.
20. van Hamont D., van Ham M.A.P.C., Bakkers J.M.J.E., Massuger L.F.A.J., Melchers W.J.G. Evaluation of the SPF10-INNO LiPA Human Papillomavirus (HPV) Genotyping Test and the Roche Linear Array HPV Genotyping Test. J Clin Microbiol 2006, 44:3122-3129.
21. Carozzi F.M., Burroni E., Bisanzi S., Puliti D., Confortini M., Giorgi Rossi P., et al. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting. J Clin Microbiol 2011, 49:1446-1451.
22. Poljak M., Ostrbenk A., Seme K., Ucakar V., Hillemanns P., Bokal E.V., et al. Comparison of clinical and analytical performance of the Abbott RealTime High Risk HPV test to the performance of Hybrid Capture 2 in population-based cervical cancer screening. J Clin Microbiol 2011, 49:1721-1729.
23. Shain E.B., Clemens J.M. A new method for robust quantitative and qualitative analysis of real-time PCR. Nucleic Acids Res 2008, 36:e91.
24. Schutzbank T.E., Ginocchio C.C. Assessment of clinical and analytical performance characteristics of an HPV genotyping test. Diagn Cytopathol 2011, doi:10.1002/dc.